DISEASES OF THE HYPOTHALAMIC–PITUITARY SYSTEM IN CHILDREN: PITUITARY GROWTH HORMONE DEFICIENCY AND DIABETES INSIPIDUS

The hypothalamus and pituitary gland regulate growth, water balance, metabolism, and pubertal development. Disorders affecting this system may present in childhood with impaired linear growth, excessive thirst and urination, dehydration, or evidence of multiple hormone deficiencies. Pituitary growth hormone deficiency (GHD) and diabetes insipidus (DI) are important, potentially treatable conditions that require timely recognition. Objective: To summarize the etiology, pathogenesis, clinical manifestations, diagnostic approach, differential diagnosis, treatment, and long-term medical follow-up of childhood GHD and DI, with emphasis on practical hospital pediatrics. Methods: A narrative review was prepared using pediatric endocrine reviews, professional society resources, clinical practice guidance, and standard clinical references concerning childhood short stature, the growth hormone–insulin-like growth factor axis, arginine vasopressin deficiency, and renal resistance to vasopressin. Results: GHD is suspected from abnormal height and growth velocity and is evaluated using auxology, IGF-1/IGFBP-3, selected growth hormone stimulation testing, assessment of other pituitary axes, and hypothalamic–pituitary MRI when indicated. DI is characterized by hypotonic polyuria and compensatory polydipsia. Paired serum and urine measurements, supervised dynamic testing when necessary, and etiological imaging help distinguish central DI from nephrogenic DI and other causes of polyuria. Treatment is cause-specific: recombinant human growth hormone for confirmed GHD, and desmopressin for central DI, while nephrogenic DI requires measures that reduce urine volume and careful fluid/electrolyte management. Conclusion: Growth charts and careful fluid-balance assessment are essential first-line clinical tools. Diagnosis should be integrated rather than based on a single laboratory result. Early specialist involvement, safe hormone replacement, surveillance for evolving pituitary deficits, and structured transition to adult care improve outcomes.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-12
DOI
https://doi.org/10.5281/zenodo.24172537
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DISEASES OF THE HYPOTHALAMIC–PITUITARY SYSTEM IN CHILDREN: PITUITARY GROWTH HORMONE DEFICIENCY AND DIABETES INSIPIDUS

Mahakpreet Singh
Zenodo (CERN European Organization for Nuclear Research)
Growth Hormone and Insulin-like Growth Factors
article

DISEASES OF THE HYPOTHALAMIC–PITUITARY SYSTEM IN CHILDREN: PITUITARY GROWTH HORMONE DEFICIENCY AND DIABETES INSIPIDUS

Mahakpreet Singh
article en

Abstract

The hypothalamus and pituitary gland regulate growth, water balance, metabolism, and pubertal development. Disorders affecting this system may present in childhood with impaired linear growth, excessive thirst and urination, dehydration, or evidence of multiple hormone deficiencies. Pituitary growth hormone deficiency (GHD) and diabetes insipidus (DI) are important, potentially treatable conditions that require timely recognition. Objective: To summarize the etiology, pathogenesis, clinical manifestations, diagnostic approach, differential diagnosis, treatment, and long-term medical follow-up of childhood GHD and DI, with emphasis on practical hospital pediatrics. Methods: A narrative review was prepared using pediatric endocrine reviews, professional society resources, clinical practice guidance, and standard clinical references concerning childhood short stature, the growth hormone–insulin-like growth factor axis, arginine vasopressin deficiency, and renal resistance to vasopressin. Results: GHD is suspected from abnormal height and growth velocity and is evaluated using auxology, IGF-1/IGFBP-3, selected growth hormone stimulation testing, assessment of other pituitary axes, and hypothalamic–pituitary MRI when indicated. DI is characterized by hypotonic polyuria and compensatory polydipsia. Paired serum and urine measurements, supervised dynamic testing when necessary, and etiological imaging help distinguish central DI from nephrogenic DI and other causes of polyuria. Treatment is cause-specific: recombinant human growth hormone for confirmed GHD, and desmopressin for central DI, while nephrogenic DI requires measures that reduce urine volume and careful fluid/electrolyte management. Conclusion: Growth charts and careful fluid-balance assessment are essential first-line clinical tools. Diagnosis should be integrated rather than based on a single laboratory result. Early specialist involvement, safe hormone replacement, surveillance for evolving pituitary deficits, and structured transition to adult care improve outcomes.

Zenodo (CERN European Organization for Nuclear Research)
Osh State University (KG)
Good health and well-being
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon